Zhitong Finance App News, Shiyao Group (01093) announced that the SYS 6088 injection (this product) developed by the Group has been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China.

This product is a recombinant humanized anti-programmed death receptor 1 (PD-1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-related antigen 4 (CTLA-4) antibody. It can specifically bind PD-1, CTLA-4 and VEGFA in the tumor microenvironment on the surface of T-cell membranes, thereby reversing T-lymphocyte (T cell) depletion in the tumor microenvironment, restoring T-cell lethal function, inhibiting angiogenesis, and promoting T-cell activation and proliferation during the immune activation phase.. The modification of the Fc terminal reduces the risk of toxicity of this product and can effectively extend its half-life.

The approved clinical indication is the treatment of advanced/metastatic solid tumors. Preclinical studies have shown that the product has a wide range of indications, shows remarkable anti-tumor effects and good safety in various models of malignant tumors, and has high clinical development value.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.